

Resource Summary Report

Generated by RRID on Apr 9, 2025

U.S. Food and Drug Administration

RRID:SCR_012945

Type: Tool

Proper Citation

U.S. Food and Drug Administration (RRID:SCR_012945)

Resource Information

URL: <http://www.fda.gov/>

Proper Citation: U.S. Food and Drug Administration (RRID:SCR_012945)

Description: An agency of the United States Department of Health and Human Services, one of the United States federal executive departments that is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics and veterinary products. The FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs. These include sanitation requirements on interstate travel and control of disease on products ranging from certain household pets to sperm donation for assisted reproduction. (Wikipedia)

Abbreviations: FDA, USFDA

Synonyms: U.S. FDA, US FDA, US Food and Drug Administration, Food and Drug Administration, United States Food and Drug Administration

Resource Type: institution

Funding:

Resource Name: U.S. Food and Drug Administration

Resource ID: SCR_012945

Alternate IDs: grid.417587.8, nlx_inv_1005074, ISNI: 0000 0001 2243 3366, Wikidata: Q204711, Crossref funder ID: 100000038

Alternate URLs: <https://ror.org/034xvzb47>

Record Creation Time: 20220129T080313+0000

Record Last Update: 20250214T183223+0000

Ratings and Alerts

No rating or validation information has been found for U.S. Food and Drug Administration.

No alerts have been found for U.S. Food and Drug Administration.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1711 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Glaviano A, et al. (2025) Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. *Journal of hematology & oncology*, 18(1), 6.

Yu T, et al. (2025) Enhanced dynamic coupling in a nuclear receptor underlies ligand activity. *The Journal of biological chemistry*, 301(2), 108081.

Starling MS, et al. (2025) The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making. *Clinical pharmacology and therapeutics*, 117(2), 343.

Matsuda K, et al. (2025) Characteristics of Drugs from Non-Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval. *Clinical pharmacology and therapeutics*, 117(1), 232.

Kong D, et al. (2025) A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly. *Clinical pharmacokinetics*, 64(1), 107.

Rodriguez R, et al. (2025) Metal Ion Signaling in Biomedicine. *Chemical reviews*, 125(2), 660.

Habibi A, et al. (2025) Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling. *Cell communication and signaling* : CCS, 23(1), 57.

Lotter W, et al. (2024) Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions. *Cancer discovery*, 14(5), 711.

, et al. (2024) Scientific Guidance on the criteria for the evaluation and on the preparation of applications for the safety assessment of post-consumer mechanical PET recycling processes intended to be used for manufacture of materials and articles in contact with food. *EFSA journal*. European Food Safety Authority, 22(7), e8879.

Smith HL, et al. (2024) ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. *British journal of cancer*, 131(5), 905.

Liu B, et al. (2024) Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain. *Signal transduction and targeted therapy*, 9(1), 131.

Lu K, et al. (2024) Research progress of drug eluting balloon in arterial circulatory system. *Frontiers in cardiovascular medicine*, 11, 1287852.

Liu X, et al. (2024) DRMref: comprehensive reference map of drug resistance mechanisms in human cancer. *Nucleic acids research*, 52(D1), D1253.

Uno T, et al. (2024) Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases. *Scientific reports*, 14(1), 25943.

Li YZ, et al. (2024) Gene therapy for chronic pain management. *Cell reports. Medicine*, 5(10), 101756.

Ding L, et al. (2024) Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials. *BMJ open*, 14(6), e077108.

Zhao B, et al. (2024) A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system. *Frontiers in pharmacology*, 15, 1333662.

Ausi Y, et al. (2024) One Step Ahead in Realizing Pharmacogenetics in Low- and Middle-Income Countries: What Should We Do? *Journal of multidisciplinary healthcare*, 17, 4863.

Gloviczki P, et al. (2024) The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. *Journal of vascular surgery. Venous and lymphatic disorders*, 12(1), 101670.

Dadvar A, et al. (2024) Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial. *PloS one*, 19(2), e0297235.